A new study published in Science Magazine has generated a comprehensive map of how the inheritance of genes may impact families affected by sarcoma. This research will lead to improved early detection of the cancer and potentially improving survival for patients
ANZSA is the proud funder of the MYTH Study currently being conducted at the Chris O’Brien Life House. The MYTH Study (Methotrexate for AYAs in The Home for adolescent and young adult (AYA) osteosarcoma patients) aims to give patients the option of treatment out of hospital and hopes to explore their perspective on the advantages and disadvantages of having treatment in this manner.
Introducing Dr. Madeleine Strach, the 2022 recipient of the ANZSA Clinical Research Fellowship which has been co-funded by The Kids Cancer Project and Rainbows for Kate.
Fernando Guimaraes is the 2021 ANZSA research grant recipient and a group leader at The University of Queensland Diamantina Institute. Australia and New Zealand Sarcoma Association spoke with Dr Guimaraes to discover how his research into harnessing our own immune system to fight sarcoma is progressing.
ANZSA is excited to announce the release of their first series of the new sarcoma guidelines. With these new guidelines, ANZSA aims to improve the care of patients with sarcoma from the initial diagnosis through to staging, treatment and follow up.
Research conducted by ANZSA featured in the rEECUR plenary presentation at the 2022 American Society of Clinical Oncology (ASCO) annual meeting in Chicago this past June.
The Precision Oncology Screening Platform Enabling Clinical Trials (PrOSPeCT) initiative will help sarcoma patients by opening up new treatment paths.
PrOSPeCT will use genomic medicine to help uncover the genetic drivers of the cancer and treat the cancer based on this information, rather than treating the cancer according to its location.
The project is led by the Australian Genomic Cancer Medicine Centre (Omico) and involves well known cancer research centres, such as the Garvan Institute and Peter MacCallum Cancer Centre.
A new small molecule is in development for desmoid tumours. The molecule known as AL102 is a potent, selective, oral gamma-secretase inhibitor (GSI).
The Australia New Zealand Sarcoma Association (ANZSA) has recently published a paper to assess the treatment pathways and outcomes of CIC-rearranged sarcoma.
CIC-rearranged sarcoma is a newly established sarcoma subtype. It is very rare which makes it hard to know how best to classify and risk stratify this subtype.
Australia New Zealand Sarcoma Association is delighted to be involved in a new clinical trial for Ewing Sarcoma patients.
We're delighted to introduce a range of ANZSA merchandise available for purchase. You can buy our merchandise for fundraising purposes or as a gift!